Jennifer Dumont

Sanofi (United States) — United States

Medicine · Health Sciences

36h-index5.0kcitations110works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hemophilia Treatment and Research(42), Platelet Disorders and Treatments(20), Monoclonal and Polyclonal Antibodies Research(17), Blood Coagulation and Thrombosis Mechanisms(14), Plant responses to elevated CO2(13)

Publications109 total

Bleed Treatment Outcomes from the XTEND-ed Study in Patients Aged 50 Years and Older
Hämostaseologie·2026
Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program
Hämostaseologie·2026
Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed
Hämostaseologie·2026
Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis
Therapeutic Advances in Hematology·2026Open Access
Patient characteristics, treatment patterns, and bleeding in people with Hemophilia A without inhibitors initiating efanesoctocog alfa in the US: An administrative claims analysis
Blood·2025Open Access
Real-world experience of efanesoctocog alfa in Hemophilia A patients in the US: A retrospective analysis
Blood·2025Open Access
Clinical outcomes up to 4 years of once-weekly efanesoctocog alfa prophylaxis in previously treated adults, adolescents, and children with severe hemophilia A: Interim analysis of the Phase 3 XTEND-ed long-term extension study
Blood·2025
HTRS2025.P2.60 SYNOVIIIUS: Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis for Synovial Hypertrophy in Patients With Hemophilia A — Study Design
Research and Practice in Thrombosis and Haemostasis·2025Open Access
HTRS2025.P1.3 Abstract of Distinction Clinical Outcomes Over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents from North America with Severe Hemophilia A in the Phase 3 XTEND-ed Long-Term Extension Study
Research and Practice in Thrombosis and Haemostasis·2025Open Access
Perioperative Management With Efanesoctocog Alfa in Patients With Haemophilia A in the Phase 3 XTEND‐1 and XTEND‐Kids Studies
Haemophilia·2025· 3 citedOpen Access
Efanesoctocog alfa treatment outcomes in subjects≥50 years of age from the XTEND-1 trial
Hämostaseologie·2025
Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program
Hämostaseologie·2025
First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study
Hämostaseologie·2025
Clinical Outcomes over 3 Years of Once-Weekly Efanesoctocog Alfa Treatment in Adults and Adolescents with Severe Hemophilia A: Second Interim Analysis from the Phase 3 XTEND-ed Long-Term Extension Study
Blood·2024· 1 cited
Unmet Needs, Factor Consumption, and Healthcare Resource Use Among People with Hemophilia a: Real-World Analysis of the Adelphi Hemophilia Disease Specific ProgrammeTM
Blood·2024· 1 cited
Real-World Experience of Switching to Prophylactic Efanesoctocog Alfa in Patients with Moderate and Severe Hemophilia a: An Analysis of the Adelphi Hemophilia Wave III Disease Specific Programme
Blood·2024Open Access
Change in Hemophilia Joint Health Score (HJHS) During the Phase 3 XTEND-1 Study of Efanesoctocog Alfa in Patients With Severe Hemophilia A
Hämostaseologie·2024
Rescue immune tolerance induction with a recombinant factor Fc-fused VIII: prospective ReITIrate study of clinical, humoral and cellular immune responses
Therapeutic Advances in Hematology·2024· 1 citedOpen Access
Experience with Accelerometer Physical Activity Tracking in Adults and Adolescents with Hemophilia A: Tool Validation Using Results from the XTEND-1 Efanesoctocog Alfa Phase 3 Trial
Blood·2023Open Access
Experiences with Efanesoctocog Alfa: Exit Interviews with Caregivers of Previously Treated Patients with Hemophilia A from the XTEND-Kids Phase 3 Clinical Trial
Blood·2023Open Access
page 1 of 6Next →

Frequent Co-authors

Alan J. Bitonti(21), Glenn F. Pierce(9), Robert Peters(9), Haiyan Jiang(7), Margaret V. Ragni(6), Amy D. Shapiro(6), Susan C. Low(6), Johnny Mahlangu(5), Jerry S. Powell(4), Neil C. Josephson(4), Roshni Kulkarni(4), John Pasi(4), Jaya Goyal(4), Alvin Luk(4), Justin T. McCue(4), David M. Stemerick(4), Pierre Dizengremel(4), Yves Jolivet(4), Didier Le Thiec(4), Nisha Jain(4)